|
1
|
Shinozaki T, Watanabe H, Yanagawa T,
Shirakura K and Takagishi K: Pirarubicin-based versus
doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother.
36:996–999. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li JJ, Di GH, Tang LC, Yu KD, Hu Z, Liu
GY, Lu JS, Wu J, Han QX, Shen ZZ and Shao ZM: Adjuvant therapy of
breast cancer with pirarubicin versus epirubicin in combination
with cyclophosphamide and 5-fluorouracil. Breast J. 17:657–660.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zou HY, Wu HL, Zhang Y, Li SF, Nie JF, Fu
HY and Yu RQ: Studying the interaction of pirarubicin with DNA and
determining pirarubicin in human urine samples: Combining
excitation-emission fluorescence matrices with second-order
calibration methods. J Fluoresc. 19:955–966. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu SY, Song SX, Lin L and Liu X:
Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin
in a human osteosarcoma cell line. Chemotherapy. 56:101–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng SE, Xiong S, Lin F, Qiao GL, Feng T,
Shen Z, Min DL, Zhang CL and Yao Y: Pirarubicin inhibits
multidrug-resistant osteosarcoma cell proliferation through
induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin.
33:832–838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu Y, Ni Z, Yan X, Dai X, Hu C, Zheng Y,
He F and Lian J: Targeting the MIR34C-5p-ATG4B-autophagy axis
enhances the sensitivity of cervical cancer cells to pirarubicin.
Autophagy. 12:1105–1117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM
and Baek KH: The expression patterns of deubiquitinating enzymes,
USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y, Lang G, Ito S, Bonnet J, Metzger
E, Sawatsubashi S, Suzuki E, Le Guezennec X, Stunnenberg HG,
Krasnov A, et al: A TFTC/STAGA module mediates histone H2A and H2B
deubiquitination, coactivates nuclear receptors, and counteracts
heterochromatin silencing. Mol Cell. 29:92–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang XY, Pfeiffer HK, Thorne AW and
McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell
marker, reverses the polycomb-catalyzed ubiquitylation of histone
H2A. Cell Cycle. 7:1522–1524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang XY, Varthi M, Sykes SM, Phillips C,
Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The
putative cancer stem cell marker USP22 is a subunit of the human
SAGA complex required for activated transcription and cell-cycle
progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiao H, Tian Y, Yang Y, Hu F, Xie X, Mei J
and Ding F: USP22 acts as an oncogene by regulating the stability
of cyclooxygenase-2 in non-small cell lung cancer. Biochem Biophys
Res Commun. 460:703–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao
B, Dong H, Wei J, Song J, Zhang DD and Fang D: USP22 antagonizes
p53 transcriptional activation by deubiquitinating Sirt1 to
suppress cell apoptosis and is required for mouse embryonic
development. Mol Cell. 46:484–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atanassov BS and Dent SY: USP22 regulates
cell proliferation by deubiquitinating the transcriptional
regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Z, Tan C, Qiu Q, Kong S, Yang H, Zhao
F, Liu Z, Li J, Kong Q, Gao B, et al: Ubiquitin-specific protease
22 is a deubiquitinase of CCNB1. Cell Discov. 1(pii): 150282015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu
H, Meng Q, Pang H, Chen X, Liu Y and Cai L: USP22 promotes tumor
progression and induces epithelial-mesenchymal transition in lung
adenocarcinoma. Lung Cancer. 88:239–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Yang Y, Li J, Liu H, Chen F, Li B,
Cui B and Liu Y: USP22 drives colorectal cancer invasion and
metastasis via epithelial-mesenchymal transition by activating AP4.
Oncotarget. 8:32683–32695. 2017.PubMed/NCBI
|
|
17
|
Glinsky GV: Death-from-cancer signatures
and stem cell contribution to metastatic cancer. Cell Cycle.
4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong J, Che X, Li X, Yu H, Gong Z and Li
W: Cloning and characterization of the human USP22 gene promoter.
PLoS One. 7:e527162012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiong J, Gong Z, Zhou X, Liu J, Jiang HE,
Wu P and Li W: p38 mitogen-activated protein kinase inhibits USP22
transcription in HeLa cells. Biomed Rep. 3:461–467. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiong J, Xu X, Zhou X, Liu J, Gong Z, Wu P
and Li W: USP22 transcriptional activity is negatively regulated by
the histone deacetylase inhibitor trichostatin A. Mol Med Rep.
10:3343–3347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ling S, Li J, Shan Q, Dai H, Lu D, Wen X,
Song P, Xie H, Zhou L, Liu J, et al: USP22 mediates the multidrug
resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1
signaling pathway. Mol Oncol. 11:682–695. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Z, Liu D, Liu S, Calderon L, Zhao G,
Turk J and Guo Z: Identification of a cAMP-response element in the
regulator of G-protein signaling-2 (RGS2) promoter as a key
cis-regulatory element for RGS2 transcriptional regulation by
angiotensin II in cultured vascular smooth muscles. J Biol Chem.
286:44646–44658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong J, Zhou X, Gong Z, Wang T, Zhang C,
Xu X, Liu J and Li W: PKA/CREB regulates the constitutive promoter
activity of the USP22 gene. Oncol Rep. 33:1505–1511. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He X, Li J, Guo W, Liu W, Yu J, Song W,
Dong L, Wang F, Yu S, Zheng Y, et al: Targeting the microRNA-21/AP1
axis by 5-fluorouracil and pirarubicin in human hepatocellular
carcinoma. Oncotarget. 6:2302–2314. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou D, Liu P, Sun DW, Chen ZJ, Hu J, Peng
SM and Liu YL: USP22 down-regulation facilitates human
retinoblastoma cell aging and apoptosis via inhibiting TERT/P53
pathway. Eur Rev Med Pharmacol Sci. 21:2785–2792. 2017.PubMed/NCBI
|
|
27
|
Tang B, Tang F, Li B, Yuan S, Xu Q,
Tomlinson S, Jin J, Hu W and He S: High USP22 expression indicates
poor prognosis in hepatocellular carcinoma. Oncotarget.
6:12654–12667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ovaa H, Kessler BM, Rolén U, Galardy PJ,
Ploegh HL and Masucci MG: Activity-based ubiquitin-specific
protease (USP) profiling of virus-infected and malignant human
cells. Proc Natl Acad Sci USA. 101:2253–2258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li K, Chen X, Liu C, Gu P, Li Z, Wu S, Xu
K, Lin T and Huang J: Pirarubicin induces an autophagic
cytoprotective response through suppression of the mammalian target
of rapamycin signaling pathway in human bladder cancer cells.
Biochem Biophys Res Commun. 460:380–385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Montminy MR, Sevarino KA, Wagner JA,
Mandel G and Goodman RH: Identification of a cyclic-AMP-responsive
element within the rat somatostatin gene. Proc Natl Acad Sci USA.
83:6682–6686. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vo N and Goodman RH: CREB-binding protein
and p300 in transcriptional regulation. J Biol Chem.
276:13505–13508. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Delghandi MP, Johannessen M and Moens U:
The cAMP signalling pathway activates CREB through PKA, p38 and
MSK1 in NIH 3T3 cells. Cell Signal. 17:1343–1351. 2005. View Article : Google Scholar : PubMed/NCBI
|
